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Regulatory T cellsAbstract The pathobiology of allergic bronchial asthma is mediated by over-expressed T helper
type 2 (Th2)-biased immune responses to harmless environmental antigens, leading to airway
inﬂammation and hyper-responsiveness. These Th2 responses are normally suppressed by func-
tional T regulatory cells (Tregs), which maintain the airway tolerance. However, the Tregs activity
is conceived to be compromised in allergic asthmatics. The curative therapy to counteract this
immune dysregulation is not available so far, and to devise such a remedy is the current research
impetus in allergic asthma therapeutics. One of the novel insights is to consider a Tregs-directed
immunoregulatory therapy that could harness endogenous Tregs to redress the Th2/Tregs imbal-
ance, thus enhancing the airway tolerance. Aspirin or acetylsalicylic acid (ASA) is a prototype
non-steroidal anti-inﬂammatory drug that possesses intriguing immunopharmacological attributes.
For example, it can enhance the number or the frequency of functional Tregs, especially natural
CD4+ CD25+ FoxP3+ Tregs, either directly or by inducing tolerogenic activity in dendritic cells
(DCs). It is also considered to be beneﬁcial for the induction of immunological tolerance in auto-rtment of Pharmacology & Toxicology, University of Veterinary and Animal Sciences, Abdul Qadir Jilani
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Can airway tolerance be promoted immunopharmacologically with Aspirin 81immunity and graft rejection. This raises the question whether ASA, if exploited optimally, may be
used to induce and harness endogenous Tregs activity for redressing Th2/Tregs imbalance in allergic
asthma. In this paper, we hypothesise that ASA may help to counteract the underlying immune dys-
regulation in allergic asthma by promoting airway tolerance. Nevertheless, the future research in
this regard will selectively need to be targeted to allergic asthma models, which are ASA insensitive,
as ASA has some adverse background and is contraindicated in asthmatics who are sensitive to it.
ª 2012 Tehran University of Medical Sciences. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license. Introduction
Bronchial asthma is a complex, heterogeneous, chronic disor-
der of the airways characterised by airway inﬂammation, air-
way hyper-responsiveness and mucous hypersecretion. There
are different phenotypes of asthma depending upon the precip-
itating factors that are broadly categorised into three main
classes: extrinsic (allergenic/atopic/immunologic); intrinsic
(non-allergenic/non-atopic/non-immunologic) and mixed (ele-
ments of extrinsic and intrinsic) [1]. Asthma is a major health
problem, particularly of the developed countries, and its prev-
alence is increasing dramatically, affecting 300 million individ-
uals worldwide.
Extrinsic or allergic bronchial asthma is the most common
type of asthma that originates from aberrant immune reactions
(both innate and adaptive) to innocuous environmental anti-
gens (allergens) [2]. In particular, the impairment of airway im-
mune tolerance due to unbalanced T helper type 2 (Th2)/T
regulatory cells (Tregs)-mediated immune responses to aller-
gens is the key step in the pathobiologic process [3,4]. Gener-
ally, Tregs wield the homeostatic balance of the immune
system in the airways by inhibiting the Th2-biased responses
to allergens in order to maintain the airway tolerance. How-
ever, their impaired expansion or functional deﬁciency may
lead to an over-developed Th2-biased immune response that
plays a central role in the pathogenesis of allergic asthma by
producing cytokines such as interleukin (IL)-4, IL-5 and IL-
13, which in turn, determine the basis of immunoglobulin E
(IgE)-mediated symptoms such as airway inﬂammation and
hyper-responsiveness [5,6]. To date, studies that have investi-
gated the link between Tregs and the development of allergic
sensitisation of the airways suggest a diminished suppressive
activity of pulmonary natural Tregs, in particular the CD4+
CD25+ Tregs [6–8]. Therapeutically, different pharmacologi-
cal groups, including inhaled glucocorticoids, bronchodilators
and antihistamines, are widely used to control the associated
symptoms in allergic asthma. However, devising a curative
therapy that could alter the underlying immune dysregulation
is still a challenging task for the medical community. To this
regard, a novel insight is to pursue a role for Tregs-directed
immunoregulatory therapy that could reverse inﬂammation,
airway hyper-responsiveness, and remodelling by inducing
the regulatory forms of pulmonary immune tolerance through
induction of the number or function of natural Tregs, either di-
rectly or by using tolerogenic dendritic cells (DCs) [9,10].
Aspirin or acetylsalicylic acid (ASA) is a prototype of non-
steroidal anti-inﬂammatory drugs, which possesses analgesic,
antipyretic, anti-inﬂammatory and anti-platelet activities, and
has a globally reliable therapeutic image with respect to cardio-
vascular disorders. The extensive research over the last decades
has implicatedASA as an important immunomodulatory agent,regulating both the innate and adaptive immune responses [11].
It is worth noting that ASA has been proposed to be beneﬁcial
for tolerance induction against autoimmunity or allograft rejec-
tion because of its ability to induce tolerogenic activity in DCs
and to enhance functional Tregs at the therapeutic dose range
[12,13]. From this viewpoint, ASAmay also be theorised to pro-
mote airway tolerance in allergic bronchial asthma; however, no
functional studies shedding light on the immunoregulatory as-
pect of ASA in relation to the underlying immune dysregulation
in allergic asthma have been reported till date. This suggests
that experimental studies ought to be endorsed in order to eval-
uate the Tregs-inducing immunopharmacological aspect of
ASA regarding allergic asthma.Hypothesis
ASA may promote airway immune tolerance and, thus, may
inhibit allergic bronchial asthma in ASA-insensitive atopic
conditions by enhancing the expansion of endogenous natural
Tregs, either directly or by inducing tolerogenic DCs. There-
fore, it may be considered a potential candidate drug for the
development of Tregs-directed immunoregulatory therapy spe-
ciﬁcally against ASA-insensitive allergic asthma (Fig. 1).
Evaluation and discussion
Harnessing Tregs to redress the Th2/Tregs imbalance in allergic
asthma: Tregs induction by tolerogenic DCs
Indeed, Tregs suppress the uncontrolled effector cell responses
to harmless environmental allergens and maintain the airway
tolerance by reversing airway inﬂammation and airway hy-
per-responsiveness in allergic airway disease [14]. However in
the case of allergic asthma, the insufﬁcient CD4+CD25+ Tregs
activity and excessive Th2-biased immune response to speciﬁc
allergens is the crucial aspect [6]. Therefore, the major focus
of current research to prevent and treat allergic asthma is to re-
dress the Th2/Tregs imbalance by devising a rational immuno-
regulatory therapy that could enhance/harness endogenous
Tregs for inducing airway tolerance [7,10]. To this end, tolero-
genic DC-based immunotherapy is being considered to be the
most reliable novel therapeutic approach that can promote air-
way tolerance via induction of natural Tregs locally, especially
CD4+CD25+ FoxP3+ Tregs [9]. The FoxP3+ Tregs are a type
of natural Tregs that are being assumed to have an important
role with respect to immune regulation in allergic asthma
[15]. Moreover, immature DCs are of particular interest as they
may possess tolerogenic capabilities through a reduced expres-
sion of antigen-speciﬁc major histocompatibility complex class
II (MHC-II) molecules and surface-associated costimulatory
Figure 1 Potential role of ASA to enhance airways tolerance by redressing Th2/Tregs imbalance in allergic asthma. ASA can induce
tolerogenic activity in DCs, which in turn cause not only the clonal expansion of natural Tregs (CD4+ CD25+ FoxP3+), but also their de
novo generation from naı¨ve T cells. In addition, it can directly increase natural Tregs, and may also suppress Th2-biased immune responses
by inhibiting IL-4 secretion. The immunotherapeutically optimal exploitation of ASA-induced/enhanced Tregs activity may have potential
implication (???) to promote airways tolerance in ASA-insensitive allergic bronchial asthmatic conditions.
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decreased IL-12 and increased IL-10 production [16].
Furthermore, allergic sensitisation may also partly result
from inappropriate activity of tolerogenic DCs [9]. Therefore,
different studies have been, and are being, conducted to
modulate DCs’ function with the aim of inducing tolerogenic
activity and, thus enhancing Tregs-directed immune tolerance
to counteract the allergic response in the atopic asthmatic con-
ditions. The most striking results in this regard have been re-
ported with vitamin D3 [17] and thrombomodulin [18].
Does the direct/indirect induction of endogenous natural Tregs
by ASA make it a potential candidate drug for allergic bronchial
asthma?
Looking from the perspective of asthma, ASA is often contra-
indicated as it may aggravate violent attacks in asthmatics,particularly the patients with ASA intolerance (ASA-induced
asthma). The generally accepted theory behind the ASA-
induced asthma pathogenesis is the occurrence of some non-
allergenic, IgE-independent mechanisms that are mediated by
cyclooxygenase-1 inhibition in ASA-sensitive patients [19].
On the other hand, data from large randomised clinical trials
suggest that low-dose ASA can reduce the relative risk of
adult-onset asthma in ASA-tolerant men and women [20,21].
This indicates that ASA may have a role in asthma prevention
in the Aspirin-tolerant population. However, the experimental/
clinical perspective of ASA, speciﬁcally in ASA-insensitive
allergic asthmatics, is not known.
Given the emerging view of redressing Th2/Tregs imbalance
for control and prevention of allergic asthma, ASA may have a
key potential role because of its ability to induce and/or
expand endogenous natural Tregs as well as inhibiting
Th2-biased responses, either directly or indirectly (Fig. 1).
Can airway tolerance be promoted immunopharmacologically with Aspirin 83For example, ASA, at the therapeutic concentration range, has
been demonstrated to act directly on T cells and selectively
augment the percentage and number of functional CD4+
CD25+ FoxP3+ Tregs in BALB/c mice [22]. CD4+ CD25+
FoxP3+ Tregs have been shown to play a critical role in the
suppression of over-expressed immune responses to environ-
mental allergens and protection against allergic asthma [23].
ASA was also reported to suppress IL-4 production and its
messenger RNA (mRNA) expression in freshly isolated and
mitogen-primed human CD4+ cells [24]. IL-4 is essential for
the up-regulation of Th2-biased immune responses.
The most convincing evidence for the potential role of ASA
to redress the Th2/Tregs imbalance in allergic asthma may be
connoted from its ability to induce tolerogenic activity in the
immature subsets of DCs at its therapeutic concentrations.
ASA acts on DCs to induce a tolerogenic phenotype character-
ised by reduced expression of costimulatory molecules (CD40,
CD80, CD83 and CD86) and an up-regulated expression of
immunoglobulin-like transcript 3 (ILT-3), a co-inhibitor
of T-cell activation required to induce Tregs [25]. The role of
ASA-induced tolerogenic DCs in airway tolerance induction
may potentially be interesting in that they have been shown
to not only augment the clonal expansion of natural CD4+
CD25+ FoxP3+ Tregs, but also induce their de novo genera-
tion by inducing hyporesponsiveness and regulatory activity
in responder-naı¨ve and memory T cells through involvement
of both cell–cell contact and inhibitory cytokine activity. A rel-
evant ﬁnding in this regard is the potential therapeutic role of
ASA-modiﬁed DCs in allograft rejection by inducing allo-spe-
ciﬁc Tregs [26]. Collectively, the impact of ASA to augment
endogenous Tregs, either directly or by inducing tolerogenic
DCs, may have implications in the facet of enhancing airway
tolerance in atopic conditions and this may be a highly rele-
vant and important topic for the future research aimed at
developing the Tregs-directed immunoregulatory therapy for
allergic bronchial asthma.
Furthermore, the immunomodulatory attributes ofASAmay
also be helpful in the immunopharmacological manipulation of
other respiratory disorders, in particular, the acute respiratory
distress syndrome (ARDS). ARDS is characterised by a neutro-
phil-mediated inﬂammatory reaction in which tumour necrosis
factor alpha (TNF-a) and IL-8 play a key role. A variety of phar-
macologic anti-inﬂammatory strategies are underway, although
most of them have been disappointing [27]. ASA may be of
special value as it not only inhibits TNF-a secretion, but also
suppresses neutrophil-mediated inﬂammatory reactions [11].Testing the hypothesis
Given the above considerations, our hypothesis may ﬁrst eth-
ically be tested in acute and chronic allergen challenge mouse
models of asthma [28,29], which more closely reﬂect the aller-
gic asthma conditions. This will also involve the development
of immunological protocols that could optimally exploit the
ASA-induced tolerogenic DCs/Tregs, thereby facilitating the
ultimate clonal expansion of natural Tregs as well as enhanc-
ing the recruitment and the differentiation of naı¨ve T cells to
Tregs activity in the airways. The conﬁrmation of this hypoth-
esis in mouse models would deﬁnitely provide an opportunity
to call for the Investigational New Drug (IND) procedures in
order to evaluate the endogenous Tregs-inducing ability ofASA as a novel and rational approach to augment airway tol-
erance by redressing the Tregs/Th2 imbalance in allergic bron-
chial asthma. However, the treatment approaches in this
regard will selectively need to be targeted to allergic asthmatic
models that would be atopic but ASA insensitive and in which
the Tregs/Th2 balance would be disturbed.
Conclusion
This proposal, though contrary to the typically perceived
adverse role of ASA in ASA-induced asthma, is based on the
likely optimal exploitation of its endogenous Tregs-inducing
immunopharmacological attributes with respect to underlying
immune dysregulation in allergic bronchial asthma. Future
research addressing the precise role of ASA speciﬁcally with
respect to immunopathogenesis of allergic asthma may serve
as the basis for the development of immunopharmacological
approaches to harness airway tolerance, thus reversing the
underlying immune dysregulation in allergic asthma. This
understanding may further enhance our ability not only to
successfully deal with the emerging concept of autoimmune
involvements in asthma [30,31], but also to enhance Tregs
activity in order to cure or prevent the diverse type of allergic
disorders [32].
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First Question: What do we already know about the
subject?
Over-expressed Th2-biased immune responses play a
key role in the immunopathogenesis of allergic
asthma. Tregs regulate the Th2 responses to allergens
and maintain airway tolerance, but they appear to be
functionally compromised in allergic asthmatics.
ASA is an immunomodulator that can induce and/
or expand natural Tregs either directly or indirectly.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts
does it have?
This paper is ﬁrst of its kind topropose thatASAmaybe
a novel candidate drug for the prevention of bronchial
asthma in atopic conditions. It may enhance airway tol-
erance by redressing the Th2/Tregs imbalance through
clonal expansion of functional Tregs, either directly or
by inducing tolerogenic activity in dendritic cells.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
The ﬁrst step to evaluate this idea should be a com-
parative immunopharmacological study in ASA-sen-
sitive and ASA-insensitive mouse models. Developing
ASA-insensitive mouse models would be ﬁrst of the
ﬁrst step.
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